- Record: found
- Abstract: not found
- Article: not found
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery
Joe Y Chang ,
Reza J Mehran ,
Lei Feng ,
Vivek Verma ,
Zhongxing Liao ,
James W Welsh ,
Steven H Lin ,
Michael S O'Reilly ,
Melenda D Jeter ,
Peter A Balter ,
Stephen E McRae ,
Donald Berry ,
John V Heymach ,
Jack A Roth ,
Mara Antonoff ,
Wayne Hofstetter ,
Ravi Rajaram ,
David Rice ,
Boris Sepesi ,
Stephen Swisher ,
Ara Vaporciyan ,
Garrett Walsh ,
Craig DeGraaf ,
Arlene Correa ,
Aileen Chen ,
Saumil Gandhi ,
Ritsuko Komaki ,
Percy Lee ,
Quynh-Nhu Nguyen ,
Matthew Ning ,
Song Gao ,
Julianne Pollard-Larkin ,
Paige Nitsch ,
Ramaswamy Sadagopan ,
Xiaochun Wang
September 2021
September 2021
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto"
id="d179274e217">A previous pooled analysis of the STARS and ROSEL trials showed higher
survival after
stereotactic ablative radiotherapy (SABR) than with surgery for operable early-stage
non-small-cell lung cancer (NSCLC), but that analysis had notable limitations. This
study reports long-term results of the revised STARS trial, in which the SABR group
was re-accrued with a larger sample size, along with a protocol-specified propensity-matched
comparison with a prospectively registered, contemporary institutional cohort of patients
who underwent video-assisted thoracoscopic surgical lobectomy with mediastinal lymph
node dissection (VATS L-MLND).
</p>